| n | PR | L-SD | SD | PD | NE | PDa |
---|
ADM/EPI + CPA | 3 | | | | 3 | | 1 |
S1 | 3 | | | 3 | | | 1 |
PTX + BEV | 23 | 5 | 1 | 9 | 5 | 3 | |
ERI | 3 | 1 | | | 1 | 1 | 2 |
DTX | 1 | | | | 1 | | |
EXE + EVE | 1 | | | | 1 | | |
CPA | 1 | | | | 1 | | |
None | 1 | | | | | | |
Pembrolizumab | 1 | | | | | 1 | |
Rx to the whole brain | 3 | 1 | | 1 | 1 | | |
- a: Progressive disease in induction therapy
- ADM doxorubicin, EPI epirubicin, CPA cyclophosphamide, PTX paclitaxel, BEV bevacizumab, ERI eribulin, DTX docetaxel, EXE exemestane, EVE everolimus, Rx radiation, PR partial response, L-SD long-lasting stable disease, SD stable disease, PD progressive disease, NE not evaluable